Cancer charity starts research programme with drug “borrowed” from industryBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39588.708125.DB (Published 22 May 2008) Cite this as: BMJ 2008;336:1155
- Susan Mayor
The charity Cancer Research UK announced this week that it has started work on its first clinical research programme in a new partnership arrangement that enables it to “borrow” candidate drugs that have been shelved by drug companies so it can further explore their potential.
The cancer research charity and its commercial arm, Cancer Research Technology, is starting the programme with the clinical development of a tyrosine kinase inhibitor, AZD0424, provided by the drug company AstraZeneca.
Under the terms of the agreement, …